If you have ovarian endometriosis cysts, you know the pain and the toll it takes on daily life. A new trial is about to test a treatment that could offer relief without surgery: ultrasound-guided ethanol sclerotherapy. This procedure uses a needle to drain the cyst and then injects ethanol to destroy the cyst lining. The trial will compare this treatment to expectant management, which means watching and waiting without active treatment. The main goal is to see if quality of life improves after six months, measured by a questionnaire called the Endometriosis Health Profile-5. Researchers also want to track pain, pain-related biomarkers, ovarian reserve, cyst size, reproductive outcomes, side effects, diagnostic accuracy, and healthcare costs. The trial will enroll 288 women with ovarian endometriomas at multiple centers. But here's the catch: this is only a protocol. No results are available yet. We don't know if the treatment works, if it's safe, or if it's better than waiting. The trial will follow participants for six months, and the findings will eventually tell us more. For now, it's a question mark, but one that could change how these cysts are managed.
Ethanol sclerotherapy for ovarian endometriomas: protocol for 288-woman RCTEthanol Injections for Endometriosis Cysts: Trial Protocol Aims to Test Quality of Life
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This publication is a protocol for a multicentre randomised controlled trial, not a report of completed results. The trial plans to enrol 288 women with ovarian endometriomas and compare ultrasound-guided ethanol sclerotherapy (EST) with expectant management.
The primary outcome is change in quality of life at 6 months, assessed using the Endometriosis Health Profile-5 (EHP-5). Secondary outcomes include pain reduction, changes in pain-related biomarkers, ovarian reserve markers, cyst size reduction, reproductive outcomes, adverse events and complications, diagnostic accuracy, and healthcare costs. Follow-up is planned for 6 months.
No main results are reported. Safety data are not reported: adverse events, serious adverse events, discontinuations, and tolerability are all listed as not reported. Limitations are not reported, and funding or conflicts of interest are not reported. Practice relevance and causality notes are also not reported.
Because this is a protocol, it cannot inform clinical decisions about ethanol sclerotherapy for ovarian endometriomas. The planned trial may eventually clarify effects on quality of life, pain, ovarian reserve, and safety, but those data are not yet available. Clinicians should continue to rely on existing evidence and await peer-reviewed results before considering EST as a management option.
How this fits prior evidence
Prior coverage has addressed non-surgical diagnosis and preoperative imaging for bowel endometriosis, showing low patient awareness despite clinical evidence. It has also covered hormonal therapies reducing pelvic pain, bone mineral density loss with hormonal suppression, and dietary components that may modulate inflammation. This protocol addresses a different intervention, ultrasound-guided ethanol sclerotherapy, for ovarian endometriomas, and a different outcome, quality of life at 6 months. It does not confirm or extend prior findings; it signals a planned randomised comparison against expectant management. No results are available to compare with prior evidence.
Common questions
What is ultrasound-guided ethanol sclerotherapy?
It's a procedure where a doctor uses ultrasound to guide a needle into an ovarian cyst. The cyst fluid is drained, and then ethanol (alcohol) is injected to destroy the cyst lining. This trial will compare it to expectant management, which means no active treatment, just monitoring.
Who can join this trial?
The trial is for women with ovarian endometriomas. It will enroll 288 women at multiple centers. If you're interested, talk to your doctor to see if you might be eligible.
What are the side effects of ethanol sclerotherapy?
The trial protocol lists adverse events and complications as outcomes to be tracked, but no side effects have been reported yet because the trial hasn't started. We won't know the risks until results are available.
How long will the trial last?
Participants will be followed for 6 months. The main goal is to see changes in quality of life at 6 months, measured by a questionnaire called the Endometriosis Health Profile-5.
More on Endometriosis
View Original Abstract ↓
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
Related in OB/GYN & Women's Health
From Other Specialties
